Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

917 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1).
Ohno S, Rai Y, Iwata H, Yamamoto N, Yoshida M, Iwase H, Masuda N, Nakamura S, Taniguchi H, Kamigaki S, Noguchi S. Ohno S, et al. Among authors: iwase h. Ann Oncol. 2010 Dec;21(12):2342-2347. doi: 10.1093/annonc/mdq249. Epub 2010 May 21. Ann Oncol. 2010. PMID: 20494961 Free article. Clinical Trial.
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
Masuda N, Sagara Y, Kinoshita T, Iwata H, Nakamura S, Yanagita Y, Nishimura R, Iwase H, Kamigaki S, Takei H, Noguchi S. Masuda N, et al. Among authors: iwase h. Lancet Oncol. 2012 Apr;13(4):345-52. doi: 10.1016/S1470-2045(11)70373-4. Epub 2012 Jan 20. Lancet Oncol. 2012. PMID: 22265697 Clinical Trial.
Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.
Noguchi S, Masuda N, Iwata H, Mukai H, Horiguchi J, Puttawibul P, Srimuninnimit V, Tokuda Y, Kuroi K, Iwase H, Inaji H, Ohsumi S, Noh WC, Nakayama T, Ohno S, Rai Y, Park BW, Panneerselvam A, El-Hashimy M, Taran T, Sahmoud T, Ito Y. Noguchi S, et al. Among authors: iwase h. Breast Cancer. 2014 Nov;21(6):703-14. doi: 10.1007/s12282-013-0444-8. Epub 2013 Feb 13. Breast Cancer. 2014. PMID: 23404211 Free PMC article. Clinical Trial.
[Results of survey conducted on perioperative chemotherapy and supportive care in primary breast cancer (JBCRG01)].
Masuda N, Toi M, Takatsuka Y, Nakamura S, Iwata H, Ohno S, Kuroi K, Kusama M, Hisamatsu K, Yamazaki K, Eisei S, Sato Y, Kaise H, Kashiwaba M, Iwase H, Kurosumi M, Tsuda H, Akiyama F; Japan Breast Cancer Research Group. Masuda N, et al. Among authors: iwase h. Gan To Kagaku Ryoho. 2007 Oct;34(10):1609-15. Gan To Kagaku Ryoho. 2007. PMID: 17940375 Japanese.
A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.
Shiba E, Yamashita H, Kurebayashi J, Noguchi S, Iwase H, Ohashi Y, Sasai K, Fujimoto T. Shiba E, et al. Among authors: iwase h. Breast Cancer. 2016 May;23(3):499-509. doi: 10.1007/s12282-015-0593-z. Epub 2015 Feb 6. Breast Cancer. 2016. PMID: 25655898 Free PMC article. Clinical Trial.
Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study.
Watanabe J, Ito Y, Ohsumi S, Mizutani M, Tashiro H, Sakurai K, Takahashi M, Saito T, Tsurutani J, Mukai H, Yoshinami T, Takao S, Yamamoto Y, Matsuoka T, Iwase H, Iwata H, Nakamura S, Saeki T. Watanabe J, et al. Among authors: iwase h. Invest New Drugs. 2017 Dec;35(6):791-799. doi: 10.1007/s10637-017-0486-4. Epub 2017 Jun 29. Invest New Drugs. 2017. PMID: 28660549 Free PMC article.
Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial.
Ohashi Y, Shiba E, Yamashita H, Kurebayashi J, Noguchi S, Iwase H, Yoshida M, Fujimoto T. Ohashi Y, et al. Among authors: iwase h. Support Care Cancer. 2018 Mar;26(3):933-945. doi: 10.1007/s00520-017-3914-2. Epub 2017 Oct 24. Support Care Cancer. 2018. PMID: 29063390 Free PMC article. Clinical Trial.
917 results